Sanja Dacic, MD, PhD
Professor of Pathology

Dr. Dacic is Director of Pathology Services - UPMC Presbyterian and Director of Thoracic Pathology Center of Excellence. She is also a member of Division of Molecular and Genomic Pathology.
Office Location:
Rm. PUH C608
200 Lothrop St.
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-8694


  • MD - University of Zagreb, Croatia, 1990
  • PhD - University of Zagreb, Croatia, 1998

Clinical Expertise

Dr. Dacic is a thoracic surgical pathologist with diagnostic expertise in neoplastic and non-neoplastic diseases of the lung, pleura and mediastinum. She is an expert in morphological and molecular diagnosis of difficult benign and malignant mesothelial proliferations. Dr. Dacic is a member of the Editorial Board for the 5th WHO Classification of Thoracic Tumors.

Research Expertise

Dr. Dacic's primary research interests relate to translational research in molecular profiling of lung carcinoma and mesotheliomas and detection of biomarkers that have potential to be used clinically for diagnosis, prognostication and treatment of lung carcinoma and mesotheliomas. These interests have resulted in numerous peer-reviewed scientific articles, book chapters, and reviews. She is a co-author of the original and revised CAP/IASLC/ AMP guidelines for molecular testing in lung cancer. She is a member of the IASLC Pathology Committee, International Mesothelioma Panel, and US and Canadian Mesothelioma Group.

Honors and Awards

  • 2011 Arthur Purdy Stout Society Young Investigator Award
  • 2017 The Texas Society of Pathologists Vernie A. Stembridge, MD Lecturship
  • 2020 International Association for the Study of Lung Cancer Fred R. Hirsch Lecturship Award for Translational Research

NIH Research

View Dr. Dacic's NIH RePORT on

Recent Publications

View Dr. Dacic's publications on PubMed

  • Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E,Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. J Thorac Oncol. 2020 May;15(5):709-740 PMID: 32004713
  • Dacic S, Roy S, Lyons MA, von der Thusen JH, Galateau-Salle F, Churg A. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ. Lung Cancer. 2020 Sep 6;149:1-4. PMID: 32932212
  • Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol. 2020 Dec;128(12):939-947 PMID: 32678499
  • Churg A, Galateau-Sallé F, Roden A, Attanoos R, von der Thüsen J, Tsao MS, Chang N, De Perrot M, Dacic S. Malignant Mesothelioma In Situ: Morphologic Features and Clinical Outcome. Mod Pathol 2020 Feb; 33(2):297-302 PMID: 31375770
  • Dacic S, Le Stang N, Husain A, Weynand B, Beasley MB, Butnor K, Chapel D, Gibbs A, Klebe S, Lantuejoul S, Roden AC, Roggli V, Tazelaar H, Vignaud JM, Galateau-Sallé F. Dacic, S. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Mod Pathol. 2020 Feb;33(2):255-262 PMID: 31273316
  • Churg A, Hwang H, Tan L, Qing G, Taher A, Tong A, Bilawich A, Dacic S. Malignant mesothelioma in situ. Histopathology. 2018 May; 72(6):1033-1038. PMID: 29350783
  • Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker E, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, TempleSmolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Jan 22. PMID: 29355391